Alnylam to Webcast Investor Event to Discuss Results From KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Alnylam to Webcast Investor Event to Discuss Results From KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Alnylam 将在美国心脏病学会科学会议上网络直播投资者活动，讨论 Zilebesiran 的 KARDIA-2 二期研究结果
Mar 20, 2024
2024 年 3 月 20 日
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 20, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, at the American College of Cardiology (ACC) Scientific Session on Sunday, April 7, 2024 at 7:00 pm ET. The event will include presentations and a Q&A session with Alnylam management and Akshay Desai, M.D., Director of the Cardiomyopathy and Heart Failure Program, Brigham and Women's Hospital.
马萨诸塞州剑桥--(美国商业资讯)--2024年3月20日-- Alnylam 制药公司 领先的RNAi治疗公司纳斯达克股票代码：ALNY）今天宣布，将在美国东部时间2024年4月7日星期日晚上7点举行的美国心脏病学会（ACC）科学会议上举办网络直播活动，讨论zilebesiran的 KARDIA-2 2期研究结果。西乐贝西兰是一种针对肝脏表达血管紧张素原（AGT）的研究性RNAi治疗药物，用于治疗高血压。该活动将包括与Alnylam管理层和布里格姆妇女医院心肌病和心力衰竭项目主任阿克沙伊·德赛医学博士的演讲和问答环节。
To access the webcast, please register online at https://edge.media-server.com/mmc/p/vmdsn9yz. Participants are requested to register a minimum of 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same webpage for six months.
要访问网络直播，请在线注册 https://edge.media-server.com/mmc/p/vmdsn9yz。请参与者在电话会议开始前至少 15 分钟注册。电话会议结束两小时后将提供电话会议的重播，并在同一个网页上存档六个月。
A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Company's website approximately two hours after the event.
电话会议的网络直播将在公司网站的 “投资者” 栏目上播出 www.alnylam.com/evets。活动结束大约两小时后，将在公司网站上提供存档的网络直播。
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam's commercial RNAi therapeutic products are ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran), which is being developed and commercialized by Alnylam's partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.
关于 Alnylam 制药
Alnylam Pharmicals（纳斯达克股票代码：ALNY）已率先将RNA干扰（RNAi）转化为一类全新的创新药物，有可能改变患有罕见和流行病但需求未得到满足的人们的生活。基于获得诺贝尔奖的科学，RNAi疗法代表了一种强大的、经过临床验证的方法，可以产生变革性药物。自 2002 年成立以来，Alnylam 一直领导 RNAI 革命 并继续实现将科学可能性变为现实的大胆愿景。Alnylam 的商用 RNAi 治疗产品是 ONPATTRO （patisiran）、AMVUTTRA （vutrisiran），GIVLAARI (givosiran)、OXLUMO (lumasiran) 和 Leqvio （inclisiran），由Alnylam的合作伙伴诺华开发和商业化。Alnylam拥有丰富的研究药物产品线，包括多个处于后期开发阶段的候选产品。Alnylam 正在执行其 “Alnylam P5x25" 该战略旨在通过可持续的创新和卓越的财务业绩为世界各地的患者提供治疗罕见病和常见疾病的变革性药物，从而使生物技术处于领先地位。Alnylam 总部位于马萨诸塞州剑桥。有关我们的员工、科学和管道的更多信息，请访问 www.alnylam.com 并在 X（前身为 Twitter）上与我们互动，网址为 @Alnylam，或者开启 领英， Facebook，或 Instagram。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320967622/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
+1-617-682-4340
Alnylam 制药公司
克里斯汀·里根·林登布姆
（投资者和媒体）
+1-617-682-4340
Josh Brodsky
(Investors)
+1-617-551-8276
乔什·布罗德斯基
（投资者）
+1-617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
来源：Alnylam Pharmicals, Inc.